Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience.
Clinical outcome of diffuse large B-cell lymphoma (DLBCL) patients with             hepatitis C virus (HCV) infection in the rituximab era remains unclear. The aim             of the present study was to compare the clinical outcome, treatment response and             hepatotoxicity in DLBCL patients who received rituximab containing immunochemotherapy             that had HCV infection and those that did not have HCV infection between January             2004 and October 2011. Of the 272 consecutive histopathologically diagnosed DLBCL             patients in our department, a total of 248 were retrospectively analyzed in the             present study. There were 28 DLBCL patients with HCV infection (the HCV group)             and 220 DLBCL patients without HCV infection (the control group). We compared             overall survival (OS), progression-free survival (PFS), treatment response and             hepatotoxicity according to HCV infection. In terms of OS (P=0.525) and PFS (P=0.759),             there were no significant differences between the HCV group and the control group.             Objective response rates were 92.9% (26/28) in the HCV group and 95.9% (211/220)             in the control group (P=0.619). In the HCV group, seven patients (25.0%) developed             hepatotoxicity during immunochemotherapy. In the control group, 35 patients (15.9%)             developed hepatotoxicity during chemotherapy. No patient required discontinuation             of immunochemotherapy owing to hepatotoxicity in either group. In terms of hepatotoxicity,             there was no significant difference between these two groups (P=0.281). In conclusion,             our study results suggested that HCV infection might not influence the clinical             course in DLBCL patients who receive rituximab-containing immunochemotherapy.
Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan. h-nishikawa@osaka-med.jrc.or.jp
Hiroki
H
Nishikawa
Mitsuru
M
Tsudo
Yukio
Y
Osaki
D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005260:Female; D016174:Hepacivirus; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D000069283:Rituximab; D012720:Severity of Illness Index; D016896:Treatment Outcome
D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab